References
- Stone JD, Chervin AS, Kranz DM. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126(2), 165–176 (2009).
- Zehn D, Lee SY, Bevan MJ. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458(7235), 211–214 (2009).
- Derby MA, Alexander-Miller MA, Tse R, Berzofsky JA. High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J. Immunol. 166(3), 1690–1697 (2001).
- Knabel M, Franz TJSchiemann M et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat. Med. 8(6), 631–637 (2002).
- Nauerth M, Weissbrich B Knall R et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci. Transl. Med. 5(192), 192ra187 (2013).
- Hombrink P, Raz YKester MGD et al. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur. J. Immunol. (2013).
- Buchholz VR, Flossdorf MHensel I et al. Disparate individual fates compose robust CD8+ T cell immunity. Science 340(6132), 630–635 (2013).
- Stemberger C, Huster KMKoffler M et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 27(6), 985–997 (2007).
- Aleksic M, Dushek OZhang H et al. Dependence of T cell antigen recognition on T cell receptor-peptide MHC confinement time. Immunity, 32(2), 163–174 (2010).
- Alam SM, Davies GMLin CM et al. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands. Immunity, 10(2), 227–237 (1999).
- Zhao Y, Bennett ADZheng Z et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179(9), 5845–5854 (2007).
- Robbins PF, Li YF, El-Gamil M et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180(9), 6116–6131 (2008).
- Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4(1), 55–62 (2003).
- Irving M, Zoete VHebeisen M et al. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287(27), 23068–23078 (2012).
- Kalergis AM, Boucheron N, Doucey M-A et al. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex. Nat. Immunol. 2(3), 229–234 (2001).
- Hebeisen M, Baitsch LPresotto D et al. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123(3), 1044–1056 (2013).
- Robbins PF, Morgan RAFeldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917–924 (2011).
- Linette GP, Stadtmauer EAMaus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6), 863–871 (2013).
- Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725–733 (2011).